Rani Therapeutics reports $45.3m cash as FDA admits oral-biologics capsule to technology scheme
The company says its funds should last until at least the close of 2027, as the RaniPill platform gains an early line of dialogue with US regulators.
Rani Therapeutics Holdings, which is developing pill-based delivery of biologic drugs, ended the third quarter of 2026 with $45.3 million in cash. The company said on 9 November, alongside its quarterly results, that this should finance operations until at least the end of 2027.
The same update disclosed that the RaniPill Capsule platform was taken into the US Food and Drug Administration's CDER Emerging Technology Program in October. The scheme allows participating companies to raise technical, manufacturing and regulatory questions with the agency at an early stage, before they reach formal submissions.
Rani was careful to note that acceptance is not an endorsement. It does not amount to approval of the platform or of any product built on it, and it says nothing about the outcome of future reviews.
In the clinic, enrolment is continuing in the expansion cohort of the Phase 1a study of RT-114. Rani expects to report data from that cohort by the end of 2026, which would fall within the period its current cash is meant to cover.
Why it matters
- The FDA programme gives Rani an early channel to the agency on technical, manufacturing and regulatory issues, but it is not an approval or a signal that one will follow.
- Rani's stated funding horizon, to at least the end of 2027, spans both its FDA engagement and the next clinical readout.
- Anyone following oral delivery of biologics should watch for the RT-114 Phase 1a expansion data, due by the end of 2026.
Company's press release (SEC filing): Rani Therapeutics Holdings, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
